AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 115 filers reported holding AKERO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,709,604 | +8.3% | 33,800 | 0.0% | 0.01% | +25.0% |
| Q2 2023 | $1,578,122 | +21.3% | 33,800 | -0.6% | 0.00% | 0.0% |
| Q1 2023 | $1,300,840 | -43.9% | 34,000 | -19.7% | 0.00% | -42.9% |
| Q4 2022 | $2,319,246 | -49.0% | 42,322 | -68.3% | 0.01% | -53.3% |
| Q3 2022 | $4,547,000 | +621.7% | 133,547 | +100.4% | 0.02% | +650.0% |
| Q2 2022 | $630,000 | -42.4% | 66,636 | -13.5% | 0.00% | -33.3% |
| Q1 2022 | $1,093,000 | +165.3% | 77,060 | +295.2% | 0.00% | +200.0% |
| Q4 2021 | $412,000 | -77.2% | 19,500 | -75.9% | 0.00% | -75.0% |
| Q3 2021 | $1,810,000 | -89.5% | 80,971 | -50.1% | 0.00% | -89.7% |
| Q2 2021 | $17,178,000 | +208.8% | 162,417 | -15.3% | 0.04% | +178.6% |
| Q1 2021 | $5,563,000 | +0.0% | 191,748 | -11.1% | 0.01% | -12.5% |
| Q4 2020 | $5,562,000 | +171.7% | 215,584 | +224.2% | 0.02% | +128.6% |
| Q3 2020 | $2,047,000 | +331.9% | 66,488 | +249.6% | 0.01% | +250.0% |
| Q2 2020 | $474,000 | – | 19,017 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |